ID
22112
Description
The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. NOTE: If this is a SERIOUS ADVERSE EVENT (AE), DO NOT COMPLETE THIS FORM, got to the SAE section and complete the SAE form. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Lien
https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Mots-clés
Versions (2)
- 08/05/2017 08/05/2017 -
- 20/05/2017 20/05/2017 -
Téléchargé le
20 mai 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Non-Serious Adverse Events Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Non-Serious Adverse Events Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Description
Non-Serious Adverse Events (AE)
Alias
- UMLS CUI-1
- C1518404
Description
Non-Serious Adverse Event
Type de données
text
Alias
- UMLS CUI [1]
- C1518404
Description
Start Date
Type de données
date
Unités de mesure
- dd/MMM/yy
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C0808070
Description
Start time
Type de données
time
Unités de mesure
- hr:min
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C1301880
Description
Outcome
Type de données
integer
Alias
- UMLS CUI [1]
- C1705586
Description
End Date
Type de données
date
Unités de mesure
- hr:min
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C0806020
Description
End Time
Type de données
time
Unités de mesure
- hr:min
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C1522314
Description
Frequency
Type de données
integer
Alias
- UMLS CUI [1]
- C3476109
Description
Maximum Intensity
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0518690
- UMLS CUI [1,2]
- C0877248
Description
Action Taken with Investigational Product
Type de données
integer
Alias
- UMLS CUI [1]
- C1704758
Description
Withdrawal
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C2349954
Description
Relationship to Investigational Product
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0085978
Similar models
Non-Serious Adverse Events Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
C0808070 (UMLS CUI [1,2])
C1301880 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])
C1522314 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,2])
C2349954 (UMLS CUI [1,2])
C0085978 (UMLS CUI [1,2])